Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. (NASDAQ: OM) is a medical technology company focused on transforming dialysis with its Tablo Hemodialysis System, and its news flow reflects both business performance and developments in kidney care. Company press releases regularly describe Outset as pioneering a first-of-its-kind technology designed to reduce the cost and complexity of dialysis across hospital and home settings.
News updates for OM commonly include quarterly financial results, where Outset reports product revenue from Tablo consoles, recurring revenue from Tablo consumables and services, gross margin trends, operating expenses, and cash balances. These releases may also include revised or updated annual revenue guidance and commentary on progress toward financial objectives.
Investors and clinicians following Outset Medical can also expect clinical and research news. The company has highlighted data from large numbers of Tablo treatments across hundreds of facilities, as well as multi-year results from hospitals that have insourced dialysis service lines using Tablo. Such announcements focus on clinical outcomes, operational metrics, and the implications of insourced dialysis models for acute-care facilities.
Outset’s news stream further covers strategic and corporate developments, such as board appointments, the creation of clinical leadership roles, and collaborations with dialysis providers to expand access to home hemodialysis using Tablo. The company also announces presentations at major healthcare and investor conferences, where management discusses its technology, business strategy, and financial performance.
This OM news page aggregates these releases so readers can follow Outset Medical’s earnings reports, clinical evidence updates, collaborations, and corporate milestones in one place.
Outset Medical (Nasdaq: OM) will release its third quarter 2025 financial results after market close on Monday, November 10, 2025. A conference call to discuss financial and operating results will be held the same day at 1:30 p.m. Pacific / 4:30 p.m. Eastern with Chair & CEO Leslie Trigg and CFO Renee Gaeta.
Interested participants must register online to receive dial-in numbers and a unique PIN; registrants are encouraged to join more than 15 minutes early. A live and archived webcast will be available on the company Investors website at https://investors.outsetmedical.com/.
Outset Medical (NASDAQ:OM) has announced a strategic collaboration with Northwest Kidney Centers to expand access to home hemodialysis using the Tablo® Hemodialysis System. Northwest Kidney Centers, pioneer of home hemodialysis programs, will integrate Tablo into their network where currently 20% of patients dialyze at home.
The Tablo system offers significant advantages, operating with standard tap water and electrical outlets, featuring a touchscreen interface and cloud connectivity. The collaboration aims to enhance patient care through Northwest Kidney Centers' comprehensive support system, including personalized training and 24/7 nursing access.
Outset Medical (NASDAQ: OM), a medical technology company focused on revolutionizing dialysis through innovative technology, has announced its participation in the upcoming 23rd Annual Morgan Stanley Global Healthcare Conference. The company's management will deliver their presentation on September 10, 2025, at 7:00 AM ET.
Investors and interested parties can access both the live presentation and archived webcast through the investor relations section of Outset Medical's website at investors.outsetmedical.com.
Outset Medical (Nasdaq: OM) reported strong Q2 2025 financial results, with net revenue reaching $31.4 million, up 15% year-over-year. The company's performance was driven by a 25% increase in Tablo console revenue and 11% growth in recurring revenue to $22.5 million.
Key highlights include improved gross margin of 37.8% (38.4% non-GAAP), a 30% reduction in operating expenses, and 60% lower cash usage compared to the previous year. The company secured a significant enterprise agreement providing Tablo access to over 100 facilities, expanding its presence to more than 900 acute and sub-acute sites in the U.S.
Following these results, Outset Medical raised its 2025 revenue guidance to $122-126 million from $115-125 million, maintaining expectations for high-30% non-GAAP gross margin and cash usage below $50 million for the year.
Outset Medical (Nasdaq: OM) has appointed Brittni McGill as its first Chief Nursing Officer, marking a significant addition to its executive team. McGill brings 18 years of nursing and hospital executive experience, previously managing over 1,400 employees at a 350-bed hospital.
In her prior role, McGill demonstrated notable success implementing Outset's Tablo system, achieving a 98% successful treatment rate and reducing central line blood stream infections by 75%. As CNO, she will lead clinical education and support programs for the dialysis nursing community, focusing on strategic outreach and clinical program innovation.
Outset Medical (Nasdaq: OM), a medical technology company focused on revolutionizing dialysis technology, has scheduled its Q2 2025 financial results announcement for August 6, 2025 after market close.
The company will host a conference call at 2:00 PM PT (5:00 PM ET) on the same day, featuring Chair and CEO Leslie Trigg and CFO Renee Gaeta. Participants can register online to receive dial-in details, and a webcast will be available on the company's investor relations website.
Outset Medical (Nasdaq: OM) has appointed healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee, replacing Dale E. Jones who has stepped down. O'Boyle brings over 20 years of healthcare leadership experience, having served as CFO of several public companies and as a board director for 6 public medical device companies.
O'Boyle's extensive board experience includes positions at Nevro Corp., GenMark Diagnostics (as Chairman), Sientra, Wright Medical Group, Zeltiq Aesthetics, and Durata Therapeutics. He previously served as CFO of Advanced Biohealing and NuVasive, and currently serves on the board of Carlsmed, a private spine surgery solutions company.
Outset Medical (Nasdaq: OM), a medical technology company focused on revolutionizing dialysis through innovative technology, has announced its upcoming participation in the RBC Capital Markets Global Health Care conference. The company's management team will present on Tuesday, May 20, 2025, at 10:30 a.m. Eastern time. Investors and interested parties can access both the live and archived webcast of the presentation through the company's investor relations website at investors.outsetmedical.com.